Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

Purpose: All patients with EGF receptor (EGFR)–mutant lung cancers eventually develop acquired resistance to EGFR tyrosine kinase inhibitors (TKI). Smaller series have identified various mechanisms of resistance, but systematic evaluation of a large number of patients to definitively establish the frequency of various mechanisms has not been conducted. Experimental Design: Patients with lung adenocarcinomas and acquired resistance to erlotinib or gefitinib enrolled onto a prospective biopsy protocol and underwent a rebiopsy after the development of acquired resistance. Histology was reviewed. Samples underwent genotyping for mutations in EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS and PIK3CA, and FISH for MET and HER2. Results: Adequate tumor samples for molecular analysis were obtained in 155 patients. Ninety-eight had second-site EGFR T790M mutations [63%; 95% confidence interval (CI), 55%–70%] and four had small cell transformation (3%, 95% CI, 0%–6%). MET amplification was seen in 4 of 75 (5%; 95% CI, 1%–13%). HER2 amplification was seen in 3 of 24 (13%; 95% CI, 3%–32%). We did not detect any acquired mutations in PIK3CA, AKT1, BRAF, ERBB2, KRAS, MEK1, or NRAS (0 of 88, 0%; 95% CI, 0%–4%). Overlap among mechanisms of acquired resistance was seen in 4%. Conclusions: This is the largest series reporting mechanisms of acquired resistance to EGFR-TKI therapy. We identified EGFR T790M as the most common mechanism of acquired resistance, whereas MET amplification, HER2 amplification, and small cell histologic transformation occur less frequently. More comprehensive methods to characterize molecular alterations in this setting are needed to improve our understanding of acquired resistance to EGFR-TKIs. Clin Cancer Res; 19(8); 2240–7. ©2013 AACR.

• Publication year

  2013

• Venue

  Clinical Cancer Research

• Publication date

  2013-03-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-12-2246PMID 23470965PMCID PMC3630270
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor

  2013cited by this paper
• Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors.

  2013cited by this paper
• EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: a case-control study of overall survival.

  2013cited by this paper
• Chemotherapy with erlotinib or chemotherapy alone in advanced NSCLC with acquired resistance to EGFR tyrosine kinase inhibitors (TKI).

  2012cited by this paper
• HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.

  2012cited by this paper
• Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1

  2012cited by this paper
• Rebiopsy of non-small cell lung cancer patients with acquired resistance to EGFR-TKI: Comparison between T790M mutation-positive and -negative populations.

  2012cited by this paper
• Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial.

  2012cited by this paper
• Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

  2012cited by this paper
• Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

  2012cited by this paper
• Treatment with EGFR tyrosine kinase inhibitors beyond progression in long-term responders to erlotinib in advanced non-small cell lung cancer: A case-control study of overall survival.

  2012cited by this paper
• Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer

  2012cited by this paper
• Delay of chemotherapy through use of post-progression erlotinib in patients with EGFR-mutant lung cancer.

  2012cited by this paper
• Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

  2011cited by this paper
• Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort

  2011cited by this paper
• Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design

  2011cited by this paper
• Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

  2011influential reference
• Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling

  2011cited by this paper
• Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay

  2011cited by this paper
• Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort

  2011cited by this paper
• Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

  2010cited by this paper
• Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation

  2010cited by this paper
• Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer

  2010cited by this paper
• Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

  2010cited by this paper
• Gender-associated differences in lung cancer: clinical characteristics and treatment outcomes in women.

  2009cited by this paper
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

  2009cited by this paper
• F1000 highlights

  2009cited by this paper
• Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

  2008cited by this paper
• Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma

  2008cited by this paper
• MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

  2007cited by this paper
• BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations

  2007cited by this paper
• Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus

  2007cited by this paper
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

  2007cited by this paper
• Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors

  2006cited by this paper
• EGFR mutations in small-cell lung cancers in patients who have never smoked.

  2006cited by this paper
• Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib

  2006cited by this paper
• Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.

  2005cited by this paper
• Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas.

  2005cited by this paper
• EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

  2005cited by this paper
• Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

  2005cited by this paper
• Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.

  2005cited by this paper
• EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

  2004cited by this paper
• Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases.

  2002cited by this paper

• EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy

  2026cites this paper
• From Gefitinib to Amivantamab: Progress and Perspectives of Therapies Targeting the Epidermal Growth Factor Receptor in the Era of Precision Oncology

  2026cites this paper
• Immunotherapy after EGFR-TKI treatment in advanced non-small cell lung cancer: Current status and future perspectives (Review)

  2026cites this paper
• Treatment options and considerations for acquired resistance in EGFR mutation-positive non-small-cell lung cancer

  2026cites this paper
• Neoadjuvant, Adjuvant and Perioperative Treatment in Early-Stage Non-Small Cell Lung Cancer (NSCLC) with Actionable Genomic Alterations: Current Landscape and Future Perspectives

  2026cites this paper
• Endostar overcomes Osimertinib-resistance mediated EGFR-activation mutation, T790M and cis-C797S triple mutations via enhancing the binding of Osimertinib to EGFR protein.

  2026cites this paper
• The STAT3-ZEB1 axis contributes to CCL2-mediated resistance to osimertinib in lung cancer.

  2026cites this paper
• A genome-wide genetic screen reveals the P2Y2-integrin axis as a stabilizer of EGFR mutants in non–small cell lung cancer (NSCLC)

  2026cites this paper
• First case report of transformation of adenocarcinoma to adenosquamous carcinoma with giant-cell carcinoma harboring HER2 mutation after zongertinib (BI 1810631) resistance

  2026cites this paper
• HDAC1-modified lamin A/C drives nuclear deformation in RB1-deficient lung adenocarcinoma.

  2026cites this paper
• Acquired CCDC6-RET Fusion After First-Line Osimertinib in Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma: A Case Report

  2026cites this paper
• Standardising MET amplification testing: limitations of the GCN ≥6 criterion.

  2026cites this paper
• Synthesis, radiolabeling, and evaluation of a 68Ga-labeled tyrosine kinase inhibitor for detecting EGFRT790M mutations in vivo

  2026cites this paper
• Targeting Mesenchymal-Epidermal Transition (MET) Aberrations in Non-Small Cell Lung Cancer: Current Challenges and Therapeutic Advances

  2026cites this paper
• Brain metastases from non-small cell lung cancer: molecular subtypes and emerging CNS-directed precision therapies

  2026cites this paper
• HER2 heterogeneity between primary cancers and brain metastases: a retrospective analysis of 185 matched pairs across multiple cancer types

  2026cites this paper
• Separase Inhibition Enhances Gefitinib Sensitivity of Lung Cancer via PTBP1/TAK1/RIPK1‐Mediated PANoptosis

  2025cites this paper
• Role of Tyrosine Kinase Inhibitor (TKI) in stage IV adenocarcinoma of lung: Early outcome from tertiary cancer hospital.

  2025influential citation
• A phase I trial of combination CAR-NK92MI immunotherapy by dual targeting MUC-1 and PD-L1 for patients with relapsed or refractory solid tumors: focus on non-small cell lung cancer

  2025cites this paper
• Real-World Outcomes of T790M Mutation Testing and Sequential Osimertinib in EGFR-Positive Advanced Non-small Cell Lung Cancer: A Revisited Strategy

  2025cites this paper
• Harnessing CRISPR/Cas9 to overcome targeted therapy resistance in non-small cell lung cancer: Advances and challenges (Review)

  2025cites this paper
• Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management

  2025cites this paper
• Detection of heterogeneous resistance mechanisms to tyrosine kinase inhibitors from cell-free DNA

  2025cites this paper
• Real-world evidence of first-line osimertinib effectiveness in Bulgarian patients: a retrospective analysis

  2025cites this paper
• The Emerging Roles of Metabolic Reprogramming in Non-Small Cell Lung Cancer Progression.

  2025cites this paper
• A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation-positive non-squamous, advanced non-small cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B study.

  2025cites this paper
• State of the art in treatment of small cell lung cancer

  2025cites this paper
• Unraveling the molecular-pathological characteristics and cellular complexity of the tumor immune microenvironment in metastatic non-small cell lung cancer

  2025cites this paper
• PD-L1 regulates c-MET phosphorylation and contributes to MET-dependent resistance to osimertinib in EGFR-mutant NSCLC

  2025cites this paper
• An Orally Available Grafted Peptide Targeting Epidermal Growth Factor Receptor Dimers Reduces Non-Small Cell Lung Cancer Tumors in Mouse Models.

  2025cites this paper
• Chryseobacterium indologenes mediates resistance to osimertinib by activating the IGF1R pathway in EGFR-mutant lung adenocarcinoma

  2025cites this paper
• A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLC.

  2025cites this paper
• GLUT1 sensitizes tumor cells to EGFR-TKIs by binding with activated EGFR and regulating its downstream signaling pathways

  2025cites this paper
• The interaction between ncRNAs and the EGFR signaling pathway in lung cancer

  2025cites this paper
• JAK-STAT Signaling in Autoimmunity and Cancer

  2025cites this paper
• Identification of novel inhibitors targeting EGFR L858R/T790M/C797S against NSCLC by molecular docking, MD simulation, and DFT approaches.

  2025cites this paper
• Advancing Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion-Mutated Non-small Cell Lung Cancer (NSCLC) Management Through Molecular Diagnostics and Targeted Therapies

  2025cites this paper
• Molecular Modelling and Designing of Aminopyrimidine Derivatives as a Small Molecular Inhibitor of T790m/C797s Double Mutations in the Kinase Domain of Epidermal Growth Factor Receptor to Arrest Tumour Angiogenesis

  2025cites this paper
• Advances in molecular pathology and therapy of non-small cell lung cancer

  2025cites this paper
• MET tyrosine kinase inhibitors in combination with EGFR tyrosine kinase inhibitors in NSCLC patients with EGFR mutations and acquired MET alterations: a systematic review and meta-analysis

  2025cites this paper
• Discovery of potent CRBN-recruiting epidermal growth factor receptor (EGFR) degraders in vitro

  2025cites this paper
• The curse of blood–brain barrier and blood–tumor barrier in malignant brain tumor treatment

  2025cites this paper
• High-dose third-generation EGFR-TKIs combined with intrathecal pemetrexed in advanced EGFR-mutant NSCLC with leptomeningeal metastases following EGFR-TKI therapy

  2025cites this paper
• An allele-specific quantitative PCR strategy for detection of EGFR T790M mutations by liquid biopsy in non-small cell lung cancer patients.

  2025cites this paper
• The current and emerging immunotherapy paradigm in small-cell lung cancer

  2025cites this paper
• Redundancy of the OST catalytic subunit facilitates therapeutic targeting of N-glycosylation.

  2025cites this paper
• Evaluating the Effectiveness of Tyrosine Kinase Inhibitors on EGFR Mutations In Vitro

  2025cites this paper
• Immune cell metabolism in cancer drug resistance: Advances in target discovery and clinical translation.

  2025cites this paper
• Novel 3,4-diaminothieno[2,3-b]thiophene-2,5-dicarbohydrazide-based scaffolds as EGFRWT, EGFRT790M, and tubulin polymerization inhibitors with anti-proliferative activity.

  2025cites this paper
• EMP3 is upregulated upon epithelial–mesenchymal transition and contributes to EGFR–tyrosine kinase inhibitor resistance in lung adenocarcinoma

  2025cites this paper
• A case of EGFR-positive lung adenocarcinoma that once transformed into small cell carcinoma but worsened into adenocarcinoma again

  2025cites this paper
• Molecular testing, treatment patterns, and outcomes in EGFR-mutated non-small cell lung cancer: the PISCES study.

  2025cites this paper
• Clinical outcomes and neuroendocrine features of transformed versus primary small-cell lung cancer.

  2025cites this paper
• Cancer-associated Fibroblasts Confer Osimertinib Resistance in Non-small Cell Lung Cancer Cells via NRG1-mediated HER3/AKT Signaling

  2025cites this paper
• NNMT-driven metabolic reprogramming creates a NAMPT druggable vulnerability and reveals liquid biopsy biomarkers for TKI resistance in EGFR-mutant NSCLC.

  2025cites this paper
• 免疫检查点抑制剂治疗致非小细胞肺癌向小细胞肺癌组织学转化：病例报道及文献复习

  2025cites this paper
• Reversed phase HPLC analysis of mobocertinib and its impurities and studies on the structure and biological activity of a new degradation product

  2025cites this paper
• Multi-omics analysis identifies the unique high-FDCSP basal cells in triple-negative breast cancer

  2025cites this paper
• Small Cell Transformation of EGFR-Mutant NSCLC Treated with Tyrosine Kinase Inhibition

  2025cites this paper
• Algorithme thérapeutique en 2025 des cancers bronchiques non à petites cellules avec mutation de l'EGFR

  2025cites this paper
• Clinical Pharmacokinetic Assessment of Lazertinib in Healthy Adult Participants: Effects of GSTM1 Genotype

  2025cites this paper
• Crossing barriers with CSF-based sequencing for leptomeningeal disease in EGFR mutant NSCLC

  2025cites this paper
• A Structural Insight Into Two Important ErbB Receptors (EGFR and HER2) and Their Relevance to Non‐Small Cell Lung Cancer

  2025cites this paper
• Targeting HER2 in lung cancers: Evolving treatment landscape and drug development strategies

  2025cites this paper
• HER2 testing: evolution and update for a companion diagnostic assay

  2025cites this paper
• The Progress of Molybdenum Disulfide 2D Nanosheets as Bionanocarriers for Drug Delivery Systems: A Groundbreaking Approach with Multiple Therapeutic Applications

  2025cites this paper
• Baseline retinoblastoma transcriptional corepressor 1 (Rb1) functional inactivation is a pre-requisite but not sufficient for small-cell histological transformation in epidermal growth factor receptor (EGFR) mutant lung adenocarcinomas post-tyrosine kinase inhibitor therapy

  2025cites this paper
• EGFR-induced lncRNA TRIDENT promotes drug resistance in non–small cell lung cancer via phospho-TRIM28-mediated DNA damage repair

  2025cites this paper
• Predicting targeted therapy resistance in non-small cell lung cancer using multimodal machine learning

  2025cites this paper
• Clinicopathologic features of histologic transformation in lung adenocarcinoma after treatment with epidermal growth factor receptor-tyrosine kinase inhibitors.

  2025cites this paper
• Proteolysis-Targeting Chimera-Doxorubicin Conjugate Nanoassemblies for Dual Treatment of EGFR-TKI Sensitive and Resistant Non-Small Cell Lung Cancer.

  2025cites this paper
• Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC: RELAY Japanese Subset

  2025cites this paper
• Application of the Human Proteome in Disease, Diagnosis, and Translation into Precision Medicine: Current Status and Future Prospects

  2025cites this paper
• Exploring the Expression of CD73 in Lung Adenocarcinoma with EGFR Genomic Alterations

  2025cites this paper
• The Interconnection Between UbcH10, p53, and EGFR in Lung Cancer Cells and Their Involvement in Treatment Response

  2025cites this paper
• Combined Use of Gefitinib and Bevacizumab in Advanced Non-Small-Cell Lung Cancer with EGFR G719S/S768I Mutations and Acquired C797S Without T790M After Osimertinib: A Case Report and Literature Review

  2025cites this paper
• Histological transformation of non-small-cell lung cancer: A neglected entity.

  2025cites this paper
• Efficacy of atezolizumab, bevacizumab, carboplatin, and paclitaxel for epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer after tyrosine kinase inhibitor failure.

  2025cites this paper
• Synthesis and evaluation of novel amino pyrimidine derivatives containing sulfonamide and their application as EGFR inhibitors.

  2025cites this paper
• Impact of Subsequent Treatment on Clinical Outcomes in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Transformed to Small-Cell Lung Cancer

  2025cites this paper
• Prevalence and molecular correlates of acquired EGFR resistance mutations in non-small cell lung cancer (NSCLC)

  2025cites this paper
• Cilengitide Derivatives Suppress TGF-β1-Induced Migration and Invasion in Afatinib-Resistant Non-small Cell Lung Cancer Cells

  2025cites this paper
• Myc family proteins: Molecular drivers of tumorigenesis and resistance in neuroendocrine tumors.

  2025cites this paper
• A Literature Review on the Treatment of Patients with Brain Metastasis from Lung Adenocarcinoma after EGFR-TKI Resistance

  2025cites this paper
• Relationship Between T790M Allele Frequency and Therapeutic Effects Before and After EGFR-TKI Administration Using Droplet Digital PCR in Non-small-cell Lung Cancer With EGFR Mutation

  2025cites this paper
• APOBEC3 Activity Promotes the Survival and Evolution of Drug-Tolerant Persister Cells during EGFR Inhibitor Resistance in Lung Cancer

  2025cites this paper
• ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1

  2025cites this paper
• Targeting Oncogenic Signaling Pathways in Lung Cancer: The Emerging Role of Nobiletin, a flavonoid from citrus peel

  2025cites this paper
• *Mechanisms of circular RNA in drug resistance of lung cancer: therapeutic targets, biomarkers, and future research directions

  2025cites this paper
• Safety and efficacy of the combination of selpercatinib with osimertinib in NSCLC: a case report and review of the literature

  2025cites this paper
• Molecular basis and therapeutic implications of binary YAPOn/YAPOff cancer classes

  2025cites this paper
• Bispecific antibody for lung cancer: mechanisms and clinical insights

  2025cites this paper
• Utilization of a Multi-modal Comprehensive Genomic and Immune Profiling Testing Strategy Results in a High Rate of Test Success and Detection of Clinically Relevant Biomarkers While Optimizing Tissue Usage

  2025cites this paper
• Impact of trifluoromethyl Ugi adducts as anticancer agents: EGFR inhibition, apoptosis induction and miRNA up-regulation

  2025cites this paper
• MET-Mutationen bei NSCLC: Vergleichende Analyse von Behandlungsstrategien

  2025cites this paper
• Correlation between treatments and outcomes of patients with EGFR-mutated non-small-cell lung cancer that transitioned into small-cell lung cancer: an international retrospective study

  2025cites this paper
• Retreatment With EGFR-Tyrosine Kinase Inhibitor After Disease Progression Following Gefitinib Induction and Chemoradiotherapy in EGFR-Mutant Stage III Non-small Lung Cancer: An Efficacy and Safety Analysis of the LOGIK0902/OLCSG0905 Study

  2025cites this paper
• Management of MET-Driven Resistance to Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer

  2025cites this paper
• Rational Design, Green Synthesis, and Biological Evaluation of Novel Imidazole Derivatives as Potent EGFR Inhibitors via One‐Pot Four‐Component Reaction

  2025cites this paper
• Patients outcomes in lung adenocarcinoma transforming to small-cell lung cancer after tyrosine kinase inhibitor therapy

  2025cites this paper